RedDress
RedDress Medical is at the forefront of innovative autologous wound care solutions, harnessing the power of whole blood to transform chronic, non-healing wound management. They are trusted by leading medical facilities and healthcare alliances, offering advanced, clinically proven healing solutions that support natural healing processes and deliver reliable outcomes. Their mission is to support healing in challenging wounds through cutting-edge research, peer-reviewed studies, and real-world case studies, aiming to improve patient quality of life and clinical results.
Industries
Nr. of Employees
small (1-50)
RedDress
Patents
Wound dressings, methods and apparatus for making same and storage and use thereof
US-10111979-B2
View DetailsWound dressings, methods and apparatus for making same and storage and use thereof
US-9180142-B2
View Details
Wound dressings, methods and apparatus for making same and storage and use thereof
US-10111979-B2
View DetailsWound dressings, methods and apparatus for making same and storage and use thereof
US-9180142-B2
View DetailsProducts
Autologous point-of-care whole blood clot system
A point-of-care system to produce an activated autologous whole blood clot for direct application to chronic, non‑healing wounds; the clot supplies a fibrin matrix, growth factors and cellular components to support wound healing.
Autologous point-of-care whole blood clot system
A point-of-care system to produce an activated autologous whole blood clot for direct application to chronic, non‑healing wounds; the clot supplies a fibrin matrix, growth factors and cellular components to support wound healing.
Services
Development and publication of clinical case studies and outcome summaries documenting wound reduction and healing timelines across multiple patient cases.
Information and resources regarding Medicare and Medicare Advantage coverage eligibility for a blood-derived product for non-healing wounds (NCD 270.3).
Development and publication of clinical case studies and outcome summaries documenting wound reduction and healing timelines across multiple patient cases.
Information and resources regarding Medicare and Medicare Advantage coverage eligibility for a blood-derived product for non-healing wounds (NCD 270.3).
Expertise Areas
- Chronic wound management
- Autologous therapeutics and biologics
- Point-of-care blood processing
- Clinical evidence generation and case-study documentation
Key Technologies
- Autologous whole blood clot therapy
- Nanoparticle-enabled blood activation
- Mold-based clot formation
- Fibrin matrix-based wound dressing
News & Updates
RedDress Medical announces that ActiGraftPro is now eligible for reimbursement from Medicare and Medicare Advantage Plans, as described by the National Coverage Determination (NCD 270.3).
RedDress Medical offers advanced autologous healing solutions that deliver superior results supported by peer review, published research, and real-world case studies.
Wound Reduction and Healing Rates
RedDress Medical reports high wound reduction and healing rates in various case studies, with some patients achieving 100% wound closure in as little as 5 to 12 weeks.
RedDress Medical announces that ActiGraftPro is now eligible for reimbursement from Medicare and Medicare Advantage Plans, as described by the National Coverage Determination (NCD 270.3).
RedDress Medical offers advanced autologous healing solutions that deliver superior results supported by peer review, published research, and real-world case studies.
Wound Reduction and Healing Rates
RedDress Medical reports high wound reduction and healing rates in various case studies, with some patients achieving 100% wound closure in as little as 5 to 12 weeks.